What makes UpToDate so powerful?

  • over 11000 topics
  • 22 specialties
  • 5,700 physician authors
  • evidence-based recommendations
See more sample topics
Find Patient Print
0 Find synonyms

Find synonyms Find exact match

Idiopathic intracranial hypertension (pseudotumor cerebri): Prognosis and treatment
Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate®
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2017 UpToDate, Inc.
Idiopathic intracranial hypertension (pseudotumor cerebri): Prognosis and treatment
View in Chinese
All topics are updated as new evidence becomes available and our peer review process is complete.
Literature review current through: Jul 2017. | This topic last updated: Jun 17, 2015.

INTRODUCTION — Idiopathic intracranial hypertension (IIH) is also called pseudotumor cerebri. It is a disorder defined by clinical criteria that include symptoms and signs isolated to those produced by increased intracranial pressure (eg, headache, papilledema, vision loss), elevated intracranial pressure with normal cerebrospinal fluid composition, and no other cause of intracranial hypertension evident on neuroimaging or other evaluations [1].

While once called benign intracranial hypertension, to distinguish it from secondary intracranial hypertension produced by a neoplastic malignancy, it is not a benign disorder. Many patients suffer from intractable, disabling headaches, and there is a risk of severe, permanent vision loss.

Recommendations for the treatment of IIH are limited by a limited number of randomized controlled trials [2,3]. Moreover, the natural history of untreated IIH is uncertain

This topic will discuss the prognosis and treatment of IIH. The epidemiology, pathogenesis, clinical features and diagnosis of this disorder are discussed separately. (See "Idiopathic intracranial hypertension (pseudotumor cerebri): Epidemiology and pathogenesis" and "Idiopathic intracranial hypertension (pseudotumor cerebri): Clinical features and diagnosis".)

PROGNOSIS — No large prospective series describe the natural history of idiopathic intracranial hypertension (IIH). A protracted course lasting months to years appears to be common [4-8]. In most patients, symptoms worsen slowly. With treatment, there is usually gradual improvement and/or stabilization, but not necessarily recovery; many patients have persistent papilledema, elevated intracranial pressure as documented on lumbar puncture, and residual visual field deficits.

A subset of individuals with IIH have a more malignant or fulminant course with rapid development of vision loss within a few weeks of symptom onset [9-11]. This is generally apparent at presentation. To limit the severity of permanent vision loss, more aggressive surgical treatment measures are considered at the outset, often with temporizing measures (eg. serial lumbar punctures, lumbar drain, and/or corticosteroids) employed until surgery can be performed.

Permanent vision loss is the major morbidity associated with IIH. An early, hospital-based study that followed 57 patients for 5 to 41 years found that 24 percent developed blindness or severe visual impairment [12]. Community and clinic-based studies have found a lower rate of severe visual loss of 6 to 14 percent [13-15].

Studies have attempted to identify patients at risk of severe permanent vision loss. Significant vision loss at presentation suggests a higher risk as does higher grade papilledema and transient visual obscurations [6,13,16]. Other risk factors more variably identified in studies include male gender, systemic hypertension, anemia, black race, younger age or onset in puberty, more severe obesity or recent weight gain, and higher opening pressure on lumbar puncture [4,6,12,15,17-19]. The presence or absence of findings on magnetic resonance imaging does not appear to predict visual outcomes [20]. Absence of papilledema appears to identify patients at low risk of vision loss [16]. (See "Idiopathic intracranial hypertension (pseudotumor cerebri): Clinical features and diagnosis", section on 'Papilledema'.)

A recurrence of symptoms may occur in 8 to 38 percent of patients after recovery from an episode of IIH or after a prolonged period of stability [12,21-23]. Weight gain is a common but not universal antecedent to recurrent IIH [21,24]. The time interval may be as long as several years [22].

TREATMENT GOALS AND MONITORING — The treatment of IIH has two major goals: the alleviation of symptoms (usually headache) and the preservation of vision.

Patients require regular follow-up visits until they stabilize. Follow-up visit intervals are individualized based on the severity, duration, and response to treatment of the clinical manifestations, but initially should be at least monthly. Each office visit should include a best corrected visual acuity, formal visual field testing, and dilated fundus examination with optic disc photographs [6].

Some patients with normal vision and minimal symptoms require no treatment other than monitoring.

Any potential agents that might cause or worsen IIH (eg, tetracycline derivatives) should be discontinued. However, this intervention alone may not be sufficient to manage IIH. (See "Idiopathic intracranial hypertension (pseudotumor cerebri): Epidemiology and pathogenesis", section on 'Medications'.)

Similarly, patients should be questioned regarding symptoms of sleep apnea; diagnostic polysomnography and treatment of sleep apnea should follow where appropriate. The association of sleep apnea and IIH is uncertain, but treatment of sleep apnea has other benefits. (See "Overview of obstructive sleep apnea in adults".)

WEIGHT LOSS — A low-sodium weight reduction program is recommended for all obese patients with IIH and appears to alleviate symptoms and signs in many but not all patients [3]. However, studies documenting benefit are limited to observations in patients who generally receive treatment with other interventions for IIH.

In a prospective cohort of 25 obese women with IIH, a low-calorie diet (425 kcal/day) for three months produced significant reductions in weight (mean 15.7 kg), intracranial pressure (mean decline 8.0 cm H2O), and symptom prevalence [25]. Vision outcomes were not reported.

One report describes nine patients placed on a salt-restricted, rapid weight reduction rice diet whose mean weight decreased from 261 to 187 pounds [26]. Papilledema improved in all patients, but visual function was not reported.

Another retrospective review compared outcomes in 38 women with IIH who had some lost weight (at least 2.5kg) to 20 women with no weight loss [27]. Final outcomes of visual acuity and visual field deficits were similar between groups; however, visual fields and papilledema improved more quickly in the weight loss group.

In another case series of 15 patients, a six percent weight loss over 24 weeks was associated with resolution of papilledema in obese IIH patients [28]. In this series, weight loss, rather than acetazolamide treatment, appeared to be temporally associated with improvement.

Finally, in a study of nine obese women with IIH and polycystic ovary syndrome, a low calorie, low carbohydrate, high protein diet achieved a median weight loss of 3 percent and improved papilledema in all but one patient [29].

Medically supervised weight loss programs or surgically induced weight reduction (eg, gastric banding or gastric bypass procedures) may be necessary in morbidly obese patients. Case series of IIH patients undergoing gastric surgery report improvement of IIH symptoms and signs including papilledema, headache, tinnitus, and cerebrospinal fluid (CSF) pressure [30-33]. These findings were observed over one to three years after surgery and were associated with mean weight loss of 45 to 58 kg. (See "Bariatric operations for management of obesity: Indications and preoperative preparation".)

These uncontrolled observations provide limited support for weight loss as a treatment for IIH. Because weight loss takes some time to achieve, other treatments for IIH are generally required at the same time.

Weight gain may be a risk factor for recurrence of IIH. (See 'Prognosis' above.)

Weight loss also has other health benefits. (See "Obesity in adults: Overview of management".)

MEDICATIONS — Medical treatment for IIH typically starts with carbonic anhydrase inhibitors. Loop diuretics may be used as an adjunct. Corticosteroids are not recommended for most patients with IIH.

Carbonic anhydrase inhibitors — Carbonic anhydrase inhibitors are believed to reduce the rate of cerebrospinal fluid production [34]. While acetazolamide is the usual first line treatment for IIH, there is no clear evidence that such treatment improves long-term prognosis [3]. In a randomized trial of 165 patients with IIH and mild visual loss, treatment with acetazolamide was associated with modest improvements in a perimetric measurement of global visual field loss, along with improvements in papilledema grade, CSF pressure, and vision-related quality of life at six months [16]. Other observational evidence supports the use of acetazolamide. Lowered CSF pressure with acetazolamide has been documented in IIH patients who underwent continuous ICP recordings [35]. Case series also suggest that in patients who can tolerate it, acetazolamide is successful in managing symptoms and stabilizing vision in 47 to 67 percent of patients [36-38]. In addition, in a long-term follow-up study of 54 patients, the average treatment duration for acetazolamide was 14 months [23]. While recurrent episodes of IIH occurred in 38 percent over a mean 6.2 years of follow-up, no recurrences occurred in the setting of ongoing acetazolamide treatment.

In adult patients, we usually start with 500 mg twice per day and advance the dose as required and tolerated by the patient. Although doses of up to 2 to 4 g per day can be administered, many patients develop dose limiting side effects at higher levels. In young children, the recommended starting dose is 25 mg/kg per day with a maximum dose of 100 mg/kg or 2 g per day [36]. The sustained release formulation (Diamox sequels) may be better tolerated by patients who are intolerant of generic acetazolamide, but are substantially more expensive.

Although a sulfa allergy is reported to be a relative contraindication to acetazolamide use, there is little clinical or pharmacologic basis for this recommendation. A true cross-reaction between sulfonamide antimicrobials and the sulfa moiety in acetazolamide and furosemide is unlikely [39]. Before prescribing acetazolamide to patients who report a sulfa allergy, we discuss the risks and benefits of treatment considering the nature of the adverse reaction comprising the reported sulfa allergy. For patients who have had major adverse reactions (eg, Stevens-Johnson syndrome, anaphylaxis), we usually consider that the risk precludes the use of acetazolamide. Allergy consultation or other desensitization protocols may be considered in these patients, but we have not employed these. (See "Sulfonamide allergy in HIV-uninfected patients".) However, if the previous sulfa-related reaction was minor, we usually proceed with acetazolamide treatment. We treated 27 patients who had a reported sulfa allergy (excluding those that reported a severe adverse reaction) with acetazolamide; only two patients suffered urticaria, and there were no severe allergic cross-reactions to sulfa [39]. Another case series documents uneventful administration of acetazolamide to three patients with reported sulfa allergy [40].

Other medication side effects of acetazolamide include digital and oral paresthesias, anorexia, malaise, metallic taste, fatigue, nausea, vomiting, electrolyte changes, mild metabolic acidosis, and kidney stones. These are usually dose-related. Monitoring of electrolytes is suggested during acetazolamide treatment.

Pregnancy, particularly the first 20 weeks, is often considered a relative contraindication to the use of acetazolamide, which is classified by the FDA as category C for pregnancy risk (table 1). Teratogenic effects have been reported with high doses in animals and a single case of a teratoma was seen in humans [7,41]. If we consider that the benefit of acetazolamide use outweighs potential risks, we do use it in pregnant women after discussion with the patient and the obstetrician and obtaining informed consent. Treatment options are somewhat limited in pregnancy as caloric restriction and the use of other diuretics are also relatively contraindicated during pregnancy [42-44].

Topiramate is an antiseizure drug that inhibits carbonic anhydrase activity. Its efficacy in the treatment of migraine headaches and its association with weight loss are features that make it an attractive potential therapeutic option in IIH. Case reports and one small unblinded study suggest that topiramate appears to have a similar efficacy to acetazolamide with regard to visual field improvement and symptom relief [45-49]. However, further study is needed before this can be considered a first-line treatment for IIH.

Other carbonic anhydrase inhibitors, such as methazolamide (Neptazane), can also be used in acetazolamide-intolerant patients. We occasionally have had apparent success with these agents.

Loop diuretics — Furosemide (20 to 40 mg per day for adults and 1 to 2 mg/kg per day in children) may be a useful adjunctive therapy to acetazolamide in IIH [36]. In one report of eight children treated with combined therapy of acetazolamide and furosemide, all had a rapid clinical response with resolution of papilledema, reduction in the mean CSF pressure after the first week of treatment, and normalization of CSF pressure within six weeks of starting therapy [50].

The same considerations discussed above regarding sulfa allergy and acetazolamide also apply to furosemide. We, after discussion of risk and benefits with patients, use furosemide in patients whose prior reactions have not included Stevens Johnson syndrome, anaphylaxis, or other severe reactions. Among 21 such patients treated with furosemide, no allergic reactions were noted [39].

Corticosteroids — Although corticosteroids (eg, prednisone) have been recommended in the past for IIH, we avoid the use of corticosteroids in IIH for the following reasons [51]:

Corticosteroids can cause weight gain that might worsen IIH.

Steroid withdrawal can cause severe rebound intracranial hypertension associated with marked visual loss.

There are significant systemic side effects from chronic corticosteroids. (See "Major side effects of systemic glucocorticoids".)

In the setting of acute visual loss, a short course of intravenous corticosteroids may be useful as a temporizing measure prior to surgical intervention in IIH. One case series describes successful use of methylprednisolone (250 mg four times a day for five days followed by an oral taper) in conjunction with acetazolamide and ranitidine in four patients with IIH and severe, acute visual loss [10]. We and others avoid using corticosteroids for long-term management of IIH [52].

Other treatments

Indomethacin - Some reports suggest that indomethacin may have efficacy in the treatment of secondary intracranial hypertension (eg, traumatic brain injury, hepatic encephalopathy) presumably by causing cerebral vasoconstriction and reducing cerebral blood flow [53]. In one report of seven patients with IIH, intravenous administration of 50 mg indomethacin was associated with prompt reduction in CSF pressure, and long-term treatment with 75 mg daily produced symptom relief, and improvement in visual fields and papilledema grade [54]. Further study of this treatment is needed before it can be recommended for use in IIH.

Iron - Iron supplementation in IIH patients with iron deficiency anemia appeared to be efficacious in a case series of six patients [55].

Headache prophylaxis — Patients with IIH can continue to have headaches despite improvement in papilledema and visual function. Medications used in the prophylactic treatment of migraine headaches are often used for headache management in IIH, if other treatments described above are not effective in this regard [56]. The choice of agent is influenced by the propensity of some of these medications (eg, valproate, tricyclic antidepressants) to produce weight gain; however, weight gain can be mitigated by use of low doses and careful monitoring of weight. (See "Preventive treatment of migraine in adults".)

Analgesic overuse or rebound headaches may be common in patients with IIH [56-58]. Efforts should be made to avoid and treat this condition. (See "Medication overuse headache: Etiology, clinical features, and diagnosis" and "Medication overuse headache: Treatment and prognosis".)

SERIAL LUMBAR PUNCTURES — Although serial lumbar punctures have been advocated for the treatment of IIH, we do not generally recommend this treatment for the following reasons [59]:

CSF reforms within six hours unless there is a CSF leak, making any treatment benefit of short-term duration only.

Lumbar punctures are uncomfortable for most patients and painful for many.

Lumbar punctures can produce complications (eg, low pressure headaches, CSF leak, CSF infection, intraspinal epidermoid tumors).

In obese patients, lumbar punctures are often technically difficult.

However, serial lumbar punctures can be a useful temporizing measure as a prelude to surgery or in patients who are pregnant who wish to avoid medical therapy [43,44,60].

SURGICAL TREATMENTS — The two main surgical procedures in IIH are optic nerve sheath fenestration and CSF shunting procedures. While not a surgical procedure per se, cerebral venous sinus stenting will also be discussed in this section as an invasive treatment option for IIH. These treatments have not been compared in a single population. Indirect comparisons of their efficacy in case series are challenged by different indications considered for intervention and different outcome measures used [61].

Indications — Patients with IIH who fail, are intolerant to, or are non-compliant with maximum medical therapy and have intractable headache or progressive visual loss appear to benefit from surgical intervention. This is the minority, less than 10 percent in one center, of patients treated for IIH [61]. Potential indications for surgical therapy include [51]:

Worsening visual field defect despite medical therapy.

Presence of visual acuity loss attributed to papilledema (ie, not due to serous detachment, macular edema, hemorrhage, or choroidal folds).

Intractable headache.

Anticipated hypotension (blood pressure treatment, renal dialysis). In theory, these might precipitate ischemic optic neuropathy in a disc that is swollen. (See "Nonarteritic anterior ischemic optic neuropathy: Epidemiology, pathogenesis, and etiologies".)

Patients unable to participate in follow-up examinations (eg, noncompliance, impaired cognition, itinerant lifestyle).

While deteriorating vision (as suggested by an abnormal visual acuity or worsening visual field deficits) is a universally accepted indication for surgical intervention, other potential considerations need to be balanced against the inherent risks of the surgical procedures and the uncertainties regarding their efficacy.

Optic nerve sheath fenestration — Optic nerve sheath fenestration (ONSF) can stabilize or improve visual loss due to papilledema in IIH [3,62-73]. There is more extensive documentation of the benefit on visual function for ONSF as compared to shunting and venous stenting [74].

In one of the largest published case series summarizing 158 operations in 86 patients, visual acuity stabilized or improved in 94 percent, while visual fields stabilized or improved in 88 percent [73]. These results are consistent with aggregated data from other smaller case series [61-66,69-72,74]. Patients with a less severe and a shorter duration of visual abnormality have better visual outcomes after ONSF [75,76].

Preservation of vision is the primary goal of ONSF. While some patients experience headache relief after ONSF, many do not [62,73]. ONSF has been associated with improvement in patients with deteriorating vision loss despite a working shunt [67,69,73]. ONSF also appears to be safe and effective in children [68,77].

Complications of ONSF occur in as many as 40 to 45 percent of patients [71,73,78,79]. Most, but not all, of these are transient and nondisabling. The more common complications include:

Temporary diplopia (due to extraocular muscle injury or to their nerve or blood supply) in 29 to 35 percent [63,71,73].

Pupillary dysfunction in up to 11 percent [63,71,73,76].

Vision loss in up to 11 percent [71]. This is usually transient, but can be catastrophic and permanent in 1.5 to 2.6 percent [69,71]. Vision loss can result from vascular complications (central retinal or branch artery occlusion, choroidal infarction), trauma (eg, operative traction), infectious optic neuritis, orbital hematoma, hemorrhage into the optic nerve sheath causing compressive hematoma, and other operative events [66,73,76,78-80].

ONSF may fail after initial benefit, requiring repeat surgery in 7 to 32 percent of eyes, depending in part on the duration of follow-up; failure may occur within months or after several years [65,70,73]. Repeat surgery appears to have a similar benefit to the original [75].

ONSF appears to be an effective procedure in patients who fail medical therapy and in our experience is preferable to CSF shunting for patients experiencing progressive vision loss.

Shunting — CSF shunting procedures include ventriculoperitoneal (VPS) or lumboperitoneal shunt (LPS). Uncontrolled observations report that these can relieve headache, diplopia, papilledema, and visual loss in patients with IIH [3,61,81-86]. However, reported outcomes are mixed, some report that 95 to 100 percent achieve stabilization or remission of visual problems [61,74,81-84], while others note that vision continued to worsen in up to 32 percent [85]. While headache relief appeared to occur in almost all patients soon after shunting, in one case series, the benefit was not universally sustained, with nearly half of patients having recurrent severe headaches within three years of surgery, despite a working shunt [87].

In addition, the rate of complications from shunting can be high. Shunt failure requiring revision is the most common complication of lumboperitoneal shunts and occurs in 48 to 86 percent of patients, with a few patients requiring multiple (10 to 38) shunt revisions [81-85,87]. In rare cases, shunt failure is accompanied by visual loss that can be rapid and severe [88]. Other common complications include shunt infection, abdominal pain, back pain, radicular pain, operative complications, and cerebrospinal fluid leak with low pressure [81-85,89,90]. Rare complications include cerebellar tonsillar herniation and syringomyelia, subdural and subarachnoid hemorrhage, and bowel perforation [89,91,92].

More recently developed technologies using advanced imaging as well as endoscopic operative techniques have improved the ability of surgeons to place catheters in the ventricles of patients with IIH who do not have ventricular enlargement. Case series suggested that ventriculoperitoneal catheters may be less prone to shunt obstruction than lumboperitoneal shunts [87,93-95]. However, the risks for low pressure, infections, and other complications were similar to lumboperitoneal shunts and requirements for shunt revision remained substantial at 40 to 60 percent.

We consider shunting with caution in IIH. However, it remains an option for patients who have failed other treatment approaches. Some patients who don't respond to optic nerve fenestration have been reported to have a clinical response to shunting [61,80].

Venous sinus stenting — Venous sinus stenting is a relatively new and somewhat controversial treatment option for IIH. Its use results from the observation that many patients with IIH have apparent stenoses of the transverse venous sinus or other cerebral veins; although whether this is a primary or secondary phenomenon is uncertain. (See "Idiopathic intracranial hypertension (pseudotumor cerebri): Epidemiology and pathogenesis", section on 'Intracranial venous hypertension'.)

A number of case series describe some centers' experience with venous stenting in patients with IIH who had apparent venous sinus obstruction on cerebral venography [96-99]. In a 2013 literature review that summarizes data on 143 patients treated with venous stenting, 88 percent of patients reported improvement of headache and 87 percent had improved visual symptoms [100]. However, among the individual series, the effects on vision were not consistently documented and follow-up was often limited. While the procedure was technically successful in 99 percent; six percent of patients had complications, including three patients with subdural hematomas requiring surgical decompression. Also, two patients were treated with thrombolytic therapy when an intraluminal thrombus was noted to develop postoperatively, despite anticoagulation treatment [97].

We and others feel that further documentation of clinical benefit from venous stenting is required before this becomes a routine part of IIH treatment [3,101].

INFORMATION FOR PATIENTS — UpToDate offers two types of patient education materials, “The Basics” and “Beyond the Basics.” The Basics patient education pieces are written in plain language, at the 5th to 6th grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10th to 12th grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.

Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on “patient info” and the keyword(s) of interest.)

Basics topics (see "Patient education: Idiopathic intracranial hypertension (pseudotumor cerebri) (The Basics)")

SUMMARY AND RECOMMENDATIONS — The major morbidity associated with IIH is loss of vision, although persistent headaches are also a source of disability and lost quality of life. Treatment recommendations for IIH are based on uncontrolled observations. There are no clinical trials that have documented the effects of treatments in IIH.

While the natural history of IIH is not known, as many as 25 percent of individuals may be at risk of severe, permanent vision loss. Symptoms usually wax and wane for several weeks, months, and even years; however, a more fulminant course with rapid vision loss is described in a minority. (See 'Prognosis' above.)

Patients require regular follow-up visits with serial examinations including visual acuity, formal visual field testing and a dilated fundus examination with optic disc photographs until they stabilize. (See 'Treatment goals and monitoring' above.)

Potential agents that might cause or worsen IIH (eg, tetracycline derivatives) should be discontinued, and treatment provided for comorbid sleep apnea and anemia if present. (See 'Treatment goals and monitoring' above and 'Other treatments' above.)

We recommend counseling and/or treatment for weight loss in all obese patients with IIH. While the reported benefit for IIH is anecdotal, weight loss is associated with other health benefits. (See 'Weight loss' above and "Obesity in adults: Overview of management".)

We suggest the use of acetazolamide as the initial treatment of patients with IIH (Grade 2B). In one clinical trial, acetazolamide was associated with improvement of visual field function and vision-related quality of life measure at six months, Topiramate and other carbonic anhydrase inhibitors are alternatives to acetazolamide; experience with these agents is more limited. (See 'Carbonic anhydrase inhibitors' above.)

Furosemide or other diuretics may provide an additional benefit to acetazolamide in patients who experience continuing symptoms on acetazolamide. (See 'Loop diuretics' above.)

Traditional headache therapies can be employed in symptomatic IIH patients. Analgesic rebound headache in particular is a common complication in IIH and should be prevented and treated as appropriate. (See 'Headache prophylaxis' above.)

We recommend against prolonged corticosteroid treatment for treatment of IIH (Grade 1B). We also suggest not using serial lumbar punctures as a primary treatment modality for IIH (Grade 2B). However, both short-term use of corticosteroids and serial lumbar punctures have been successfully used as short term temporizing measures in patients with rapidly progressive symptoms who are waiting more definitive surgical therapy. (See 'Corticosteroids' above and 'Serial lumbar punctures' above.)

For patients with progressing visual loss, we recommend surgical intervention with optic nerve sheath fenestration (ONSF) and/or a CSF shunting procedure (Grade 1B). The choice of surgical procedure is individualized based upon available expertise and patient preference. We prefer ONSF rather than shunting for most patients because of better documentation of efficacy and a lower rate of severe side effects. However, headache response may be superior with shunting. Patients who do not respond to one treatment, may respond to the other. Neither intervention is a panacea; serious complications may occur, and failure rates and symptom recurrence are common, requiring long-term follow-up of all patients. (See 'Surgical treatments' above.)

Use of UpToDate is subject to the  Subscription and License Agreement.


  1. Friedman DI, Jacobson DM. Diagnostic criteria for idiopathic intracranial hypertension. Neurology 2002; 59:1492.
  2. Lueck C, McIlwaine G. Interventions for idiopathic intracranial hypertension. Cochrane Database Syst Rev 2005; :CD003434.
  3. Biousse V, Bruce BB, Newman NJ. Update on the pathophysiology and management of idiopathic intracranial hypertension. J Neurol Neurosurg Psychiatry 2012; 83:488.
  4. Wall M, George D. Idiopathic intracranial hypertension. A prospective study of 50 patients. Brain 1991; 114 ( Pt 1A):155.
  5. Celebisoy N, Seçil Y, Akyürekli O. Pseudotumor cerebri: etiological factors, presenting features and prognosis in the western part of Turkey. Acta Neurol Scand 2002; 106:367.
  6. Wall M. Sensory visual testing in idiopathic intracranial hypertension: measures sensitive to change. Neurology 1990; 40:1859.
  7. Acheson JF. Idiopathic intracranial hypertension and visual function. Br Med Bull 2006; 79-80:233.
  8. Salman MS, Kirkham FJ, MacGregor DL. Idiopathic "benign" intracranial hypertension: case series and review. J Child Neurol 2001; 16:465.
  9. Thambisetty M, Lavin PJ, Newman NJ, Biousse V. Fulminant idiopathic intracranial hypertension. Neurology 2007; 68:229.
  10. Liu GT, Glaser JS, Schatz NJ. High-dose methylprednisolone and acetazolamide for visual loss in pseudotumor cerebri. Am J Ophthalmol 1994; 118:88.
  11. Kidron D, Pomeranz S. Malignant pseudotumor cerebri. Report of two cases. J Neurosurg 1989; 71:443.
  12. Corbett JJ, Savino PJ, Thompson HS, et al. Visual loss in pseudotumor cerebri. Follow-up of 57 patients from five to 41 years and a profile of 14 patients with permanent severe visual loss. Arch Neurol 1982; 39:461.
  13. Rowe FJ, Sarkies NJ. Visual outcome in a prospective study of idiopathic intracranial hypertension. Arch Ophthalmol 1999; 117:1571.
  14. Radhakrishnan K, Ahlskog JE, Cross SA, et al. Idiopathic intracranial hypertension (pseudotumor cerebri). Descriptive epidemiology in Rochester, Minn, 1976 to 1990. Arch Neurol 1993; 50:78.
  15. Bruce BB, Preechawat P, Newman NJ, et al. Racial differences in idiopathic intracranial hypertension. Neurology 2008; 70:861.
  16. NORDIC Idiopathic Intracranial Hypertension Study Group Writing Committee, Wall M, McDermott MP, et al. Effect of acetazolamide on visual function in patients with idiopathic intracranial hypertension and mild visual loss: the idiopathic intracranial hypertension treatment trial. JAMA 2014; 311:1641.
  17. Stiebel-Kalish H, Kalish Y, Lusky M, et al. Puberty as a risk factor for less favorable visual outcome in idiopathic intracranial hypertension. Am J Ophthalmol 2006; 142:279.
  18. Bruce BB, Kedar S, Van Stavern GP, et al. Idiopathic intracranial hypertension in men. Neurology 2009; 72:304.
  19. Bruce BB, Kedar S, Van Stavern GP, et al. Atypical idiopathic intracranial hypertension: normal BMI and older patients. Neurology 2010; 74:1827.
  20. Saindane AM, Bruce BB, Riggeal BD, et al. Association of MRI findings and visual outcome in idiopathic intracranial hypertension. AJR Am J Roentgenol 2013; 201:412.
  21. Taktakishvili O, Shah VA, Shahbaz R, Lee AG. Recurrent idiopathic intracranial hypertension. Ophthalmology 2008; 115:221.
  22. Shah VA, Kardon RH, Lee AG, et al. Long-term follow-up of idiopathic intracranial hypertension: the Iowa experience. Neurology 2008; 70:634.
  23. Kesler A, Hadayer A, Goldhammer Y, et al. Idiopathic intracranial hypertension: risk of recurrences. Neurology 2004; 63:1737.
  24. Ko MW, Chang SC, Ridha MA, et al. Weight gain and recurrence in idiopathic intracranial hypertension: a case-control study. Neurology 2011; 76:1564.
  25. Sinclair AJ, Burdon MA, Nightingale PG, et al. Low energy diet and intracranial pressure in women with idiopathic intracranial hypertension: prospective cohort study. BMJ 2010; 341:c2701.
  26. Newborg B. Pseudotumor cerebri treated by rice reduction diet. Arch Intern Med 1974; 133:802.
  27. Kupersmith MJ, Gamell L, Turbin R, et al. Effects of weight loss on the course of idiopathic intracranial hypertension in women. Neurology 1998; 50:1094.
  28. Johnson LN, Krohel GB, Madsen RW, March GA Jr. The role of weight loss and acetazolamide in the treatment of idiopathic intracranial hypertension (pseudotumor cerebri). Ophthalmology 1998; 105:2313.
  29. Glueck CJ, Golnik KC, Aregawi D, et al. Changes in weight, papilledema, headache, visual field, and life status in response to diet and metformin in women with idiopathic intracranial hypertension with and without concurrent polycystic ovary syndrome or hyperinsulinemia. Transl Res 2006; 148:215.
  30. Sugerman HJ, Felton WL 3rd, Salvant JB Jr, et al. Effects of surgically induced weight loss on idiopathic intracranial hypertension in morbid obesity. Neurology 1995; 45:1655.
  31. Sugerman HJ, Felton WL 3rd, Sismanis A, et al. Gastric surgery for pseudotumor cerebri associated with severe obesity. Ann Surg 1999; 229:634.
  32. Chandra V, Dutta S, Albanese CT, et al. Clinical resolution of severely symptomatic pseudotumor cerebri after gastric bypass in an adolescent. Surg Obes Relat Dis 2007; 3:198.
  33. Nadkarni T, Rekate HL, Wallace D. Resolution of pseudotumor cerebri after bariatric surgery for related obesity. Case report. J Neurosurg 2004; 101:878.
  34. McCarthy KD, Reed DJ. The effect of acetazolamide and furosemide on cerebrospinal fluid production and choroid plexus carbonic anhydrase activity. J Pharmacol Exp Ther 1974; 189:194.
  35. Gücer G, Viernstein L. Long-term intracranial pressure recording in the management of pseudotumor cerebri. J Neurosurg 1978; 49:256.
  36. Matthews YY. Drugs used in childhood idiopathic or benign intracranial hypertension. Arch Dis Child Educ Pract Ed 2008; 93:19.
  37. Youroukos S, Psychou F, Fryssiras S, et al. Idiopathic intracranial hypertension in children. J Child Neurol 2000; 15:453.
  38. Warman R. Management of pseudotumor cerebri in children. Int Pediatr 2000; 15:147.
  39. Lee AG, Anderson R, Kardon RH, Wall M. Presumed "sulfa allergy" in patients with intracranial hypertension treated with acetazolamide or furosemide: cross-reactivity, myth or reality? Am J Ophthalmol 2004; 138:114.
  40. Platt D, Griggs RC. Use of acetazolamide in sulfonamide-allergic patients with neurologic channelopathies. Arch Neurol 2012; 69:527.
  41. Lee AG, Pless M, Falardeau J, et al. The use of acetazolamide in idiopathic intracranial hypertension during pregnancy. Am J Ophthalmol 2005; 139:855.
  42. Digre KB, Corbett JJ. Pseudotumor cerebri in men. Arch Neurol 1988; 45:866.
  43. Huna-Baron R, Kupersmith MJ. Idiopathic intracranial hypertension in pregnancy. J Neurol 2002; 249:1078.
  44. Digre KB, Varner MW, Corbett JJ. Pseudotumor cerebri and pregnancy. Neurology 1984; 34:721.
  45. Celebisoy N, Gökçay F, Sirin H, Akyürekli O. Treatment of idiopathic intracranial hypertension: topiramate vs acetazolamide, an open-label study. Acta Neurol Scand 2007; 116:322.
  46. Pagan FL, Restrepo L, Balish M, et al. A new drug for an old condition? Headache 2002; 42:695.
  47. Shah VA, Fung S, Shahbaz R, et al. Idiopathic intracranial hypertension. Ophthalmology 2007; 114:617.
  48. Friedman, DI, Eller, PF. Topiramate for the treatment of idiopathic intracranial hypertension. Headache 2003; 43:592.
  49. Finsterer J, Földy D, Fertl E. Topiramate resolves headache from pseudotumor cerebri. J Pain Symptom Manage 2006; 32:401.
  50. Schoeman JF. Childhood pseudotumor cerebri: clinical and intracranial pressure response to acetazolamide and furosemide treatment in a case series. J Child Neurol 1994; 9:130.
  51. Corbett JJ, Thompson HS. The rational management of idiopathic intracranial hypertension. Arch Neurol 1989; 46:1049.
  52. Friedman DI, Jacobson DM. Idiopathic intracranial hypertension. J Neuroophthalmol 2004; 24:138.
  53. Rasmussen M. Treatment of elevated intracranial pressure with indomethacin: friend or foe? Acta Anaesthesiol Scand 2005; 49:341.
  54. Förderreuther S, Straube A. Indomethacin reduces CSF pressure in intracranial hypertension. Neurology 2000; 55:1043.
  55. Biousse V, Rucker JC, Vignal C, et al. Anemia and papilledema. Am J Ophthalmol 2003; 135:437.
  56. Friedman DI, Rausch EA. Headache diagnoses in patients with treated idiopathic intracranial hypertension. Neurology 2002; 58:1551.
  57. Wang SJ, Silberstein SD, Patterson S, Young WB. Idiopathic intracranial hypertension without papilledema: a case-control study in a headache center. Neurology 1998; 51:245.
  58. Mathew NT, Ravishankar K, Sanin LC. Coexistence of migraine and idiopathic intracranial hypertension without papilledema. Neurology 1996; 46:1226.
  59. Corbett JJ, Mehta MP. Cerebrospinal fluid pressure in normal obese subjects and patients with pseudotumor cerebri. Neurology 1983; 33:1386.
  60. Evans RW, Friedman DI. Expert opinion: the management of pseudotumor cerebri during pregnancy. Headache 2000; 40:495.
  61. Fonseca PL, Rigamonti D, Miller NR, Subramanian PS. Visual outcomes of surgical intervention for pseudotumour cerebri: optic nerve sheath fenestration versus cerebrospinal fluid diversion. Br J Ophthalmol 2014; 98:1360.
  62. Acheson JF, Green WT, Sanders MD. Optic nerve sheath decompression for the treatment of visual failure in chronic raised intracranial pressure. J Neurol Neurosurg Psychiatry 1994; 57:1426.
  63. Brourman ND, Spoor TC, Ramocki JM. Optic nerve sheath decompression for pseudotumor cerebri. Arch Ophthalmol 1988; 106:1378.
  64. Corbett JJ, Nerad JA, Tse DT, Anderson RL. Results of optic nerve sheath fenestration for pseudotumor cerebri. The lateral orbitotomy approach. Arch Ophthalmol 1988; 106:1391.
  65. Goh KY, Schatz NJ, Glaser JS. Optic nerve sheath fenestration for pseudotumor cerebri. J Neuroophthalmol 1997; 17:86.
  66. Kelman SE, Heaps R, Wolf A, Elman MJ. Optic nerve decompression surgery improves visual function in patients with pseudotumor cerebri. Neurosurgery 1992; 30:391.
  67. Kelman SE, Sergott RC, Cioffi GA, et al. Modified optic nerve decompression in patients with functioning lumboperitoneal shunts and progressive visual loss. Ophthalmology 1991; 98:1449.
  68. Lee AG, Patrinely JR, Edmond JC. Optic nerve sheath decompression in pediatric pseudotumor cerebri. Ophthalmic Surg Lasers 1998; 29:514.
  69. Sergott RC, Savino PJ, Bosley TM. Modified optic nerve sheath decompression provides long-term visual improvement for pseudotumor cerebri. Arch Ophthalmol 1988; 106:1384.
  70. Spoor TC, McHenry JG. Long-term effectiveness of optic nerve sheath decompression for pseudotumor cerebri. Arch Ophthalmol 1993; 111:632.
  71. Plotnik JL, Kosmorsky GS. Operative complications of optic nerve sheath decompression. Ophthalmology 1993; 100:683.
  72. Hupp SL, Glaser JS, Frazier-Byrne S. Optic nerve sheath decompression. Review of 17 cases. Arch Ophthalmol 1987; 105:386.
  73. Banta JT, Farris BK. Pseudotumor cerebri and optic nerve sheath decompression. Ophthalmology 2000; 107:1907.
  74. Feldon SE. Visual outcomes comparing surgical techniques for management of severe idiopathic intracranial hypertension. Neurosurg Focus 2007; 23:E6.
  75. Spoor TC, Ramocki JM, Madion MP, Wilkinson MJ. Treatment of pseudotumor cerebri by primary and secondary optic nerve sheath decompression. Am J Ophthalmol 1991; 112:177.
  76. Chandrasekaran S, McCluskey P, Minassian D, Assaad N. Visual outcomes for optic nerve sheath fenestration in pseudotumour cerebri and related conditions. Clin Exp Ophthalmol 2006; 34:661.
  77. Thuente DD, Buckley EG. Pediatric optic nerve sheath decompression. Ophthalmology 2005; 112:724.
  78. Brodsky MC, Rettele GA. Protracted postsurgical blindness with visual recovery following optic nerve sheath fenestration. Arch Ophthalmol 1997; 115:1473.
  79. Rizzo JF 3rd, Lessell S. Choroidal infarction after optic nerve sheath fenestration. Ophthalmology 1994; 101:1622.
  80. Mauriello JA Jr, Shaderowfsky P, Gizzi M, Frohman L. Management of visual loss after optic nerve sheath decompression in patients with pseudotumor cerebri. Ophthalmology 1995; 102:441.
  81. Burgett RA, Purvin VA, Kawasaki A. Lumboperitoneal shunting for pseudotumor cerebri. Neurology 1997; 49:734.
  82. Eggenberger ER, Miller NR, Vitale S. Lumboperitoneal shunt for the treatment of pseudotumor cerebri. Neurology 1996; 46:1524.
  83. Johnston I, Besser M, Morgan MK. Cerebrospinal fluid diversion in the treatment of benign intracranial hypertension. J Neurosurg 1988; 69:195.
  84. Chumas PD, Kulkarni AV, Drake JM, et al. Lumboperitoneal shunting: a retrospective study in the pediatric population. Neurosurgery 1993; 32:376.
  85. Rosenberg ML, Corbett JJ, Smith C, et al. Cerebrospinal fluid diversion procedures in pseudotumor cerebri. Neurology 1993; 43:1071.
  86. Lundar T, Nornes H. Pseudotumour cerebri-neurosurgical considerations. Acta Neurochir Suppl (Wien) 1990; 51:366.
  87. McGirt MJ, Woodworth G, Thomas G, et al. Cerebrospinal fluid shunt placement for pseudotumor cerebri-associated intractable headache: predictors of treatment response and an analysis of long-term outcomes. J Neurosurg 2004; 101:627.
  88. Liu GT, Volpe NJ, Schatz NJ, et al. Severe sudden visual loss caused by pseudotumor cerebri and lumboperitoneal shunt failure. Am J Ophthalmol 1996; 122:129.
  89. Chumas PD, Armstrong DC, Drake JM, et al. Tonsillar herniation: the rule rather than the exception after lumboperitoneal shunting in the pediatric population. J Neurosurg 1993; 78:568.
  90. Sell JJ, Rupp FW, Orrison WW Jr. Iatrogenically induced intracranial hypotension syndrome. AJR Am J Roentgenol 1995; 165:1513.
  91. Padmanabhan R, Crompton D, Burn D, Birchall D. Acquired Chiari 1 malformation and syringomyelia following lumboperitoneal shunting for pseudotumour cerebri. J Neurol Neurosurg Psychiatry 2005; 76:298.
  92. Suri A, Pandey P, Mehta VS. Subarachnoid hemorrhage and intracereebral hematoma following lumboperitoneal shunt for pseudotumor cerebri: a rare complication. Neurol India 2002; 50:508.
  93. Bynke G, Zemack G, Bynke H, Romner B. Ventriculoperitoneal shunting for idiopathic intracranial hypertension. Neurology 2004; 63:1314.
  94. Maher CO, Garrity JA, Meyer FB. Refractory idiopathic intracranial hypertension treated with stereotactically planned ventriculoperitoneal shunt placement. Neurosurg Focus 2001; 10:E1.
  95. Woodworth GF, McGirt MJ, Elfert P, et al. Frameless stereotactic ventricular shunt placement for idiopathic intracranial hypertension. Stereotact Funct Neurosurg 2005; 83:12.
  96. Owler BK, Parker G, Halmagyi GM, et al. Pseudotumor cerebri syndrome: venous sinus obstruction and its treatment with stent placement. J Neurosurg 2003; 98:1045.
  97. Higgins JN, Cousins C, Owler BK, et al. Idiopathic intracranial hypertension: 12 cases treated by venous sinus stenting. J Neurol Neurosurg Psychiatry 2003; 74:1662.
  98. Donnet A, Metellus P, Levrier O, et al. Endovascular treatment of idiopathic intracranial hypertension: clinical and radiologic outcome of 10 consecutive patients. Neurology 2008; 70:641.
  99. Ahmed RM, Wilkinson M, Parker GD, et al. Transverse sinus stenting for idiopathic intracranial hypertension: a review of 52 patients and of model predictions. AJNR Am J Neuroradiol 2011; 32:1408.
  100. Puffer RC, Mustafa W, Lanzino G. Venous sinus stenting for idiopathic intracranial hypertension: a review of the literature. J Neurointerv Surg 2013; 5:483.
  101. Friedman DI. Cerebral venous pressure, intra-abdominal pressure, and dural venous sinus stenting in idiopathic intracranial hypertension. J Neuroophthalmol 2006; 26:61.
Topic 5253 Version 11.0

All topics are updated as new information becomes available. Our peer review process typically takes one to six weeks depending on the issue.